Abstract
Astrocytes harbour functional receptors to many neurotransmitters, including substance P (SP), an undecapeptide belonging to the tachykinin family of peptide transmitters. SP activates malignant glial cells to induce cytokine release and proliferation, both responses being relevant for tumour progression. In tumours developed in nude mice transplanted subcutaneously (s.c.) to U373 MG human glioma cells, the presence of SP was observed at immunohistochemistry. Although the administration of exogenous SP did not significantly affect the size or development of U373 MG xenograft, a role of SP in supporting glioma progression in vivo was highlighted by the tumour growth inhibition induced by highly specific and selective human tachykinin NK1receptor antagonists (MEN 11467 and MEN 11149). The anti-tumour activity of MEN 11467 was observed both with s.c. or intravenous treatments and was partially reverted by the concomitant administration of exogenous SP. Doxorubicin did not show any activity in controlling U373 MG growth in this in vivo model. A novel therapeutic approach to treat malignant gliomas with tachykinin NK1receptor antagonists is suggested by these findings. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allen JM, Hoyle NR, Yeats JC, Ghatei MA, Thomas DG and Bloom SR (1985) Neuropeptides in neurological tumours. J Neuro-Oncol 3: 197–202
Cirillo R, Astolfi M, Ciucci A, Palma C, Parlani M, Lopez G, Conte B, Terracciano R, Fincham CI, Sisto A, Maggi CA and Manzini S (1998 a) Pharmacology of MEN 11467, a potent, selective and orally effective pseudopeptide tachykinin NK-1 antagonist. Naun Schmied Arch Pharmacol 358: R324
Cirillo R, Astolfi M, Conte B, Lopez G, Parlani M, Terracciano R, Fincham CI and Manzini S (1998 b) Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist. Eur J Pharmacol 341: 201–209
Geran RI, Greenberg NH, MacDonald MM, Schumacher AM and Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3: 1–88
Gillespie GY (1996) Cytokines as modulators of malignant glioma progression. In: Cytokines and the CNS, Ransohoff RM, Beneviste EM (eds), pp. 269–286. CRC Press: Boca Raton
Gitter BD, Regoli D, Howbert JJ, Glasebrook AL and Waters DC (1994) Interleukin-6 secretion from human astrocytoma cells induced by substance P. J Neuroimmunol 51: 101–108
Giuliani FC, Karimullah AZ and Kaplan NO (1981) Therapeutic response of human tumor xenografts in athymic nude mice to doxorubicin. Cancer Res 41: 325–335
Henning IM, Laissue JA, Horisberger U and Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61: 786–792
Heuillet E, Menager J, Faradin V, Flamand O, Bock M, Garret C, Crespo A, Fallourd AM and Doble A (1993) Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U373 MG. J Neurochem 60: 868–876
Hochberg F and Pruitt A (1987) Neoplastic diseases of the central nervous system. In: Harrison’s Principles of Internal Medicine, 11th edn. Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (eds), pp. 1968–1980. McGraw-Hill: New York
Humpel C, Marksteiner J and Saria A (1996) Glial cell-derived neurotrophic factor enhances biosynthesis of substance P in striatal neurons in vitro. Cell Tissue Res 286: 249–255
Jennings MT, Maciunas RJ, Carver R, Bascom CC, Juneau P, Misulis K and Moses HL (1991) TGFβ1 and TGFβ2 are potential growth regulators for low-grade and malignant glioma in vitro: Evidence in support of an autocrine hypothesis. Int J Cancer 49: 129–139
Kostyk SK, Kowall NW and Hauser SL (1989) Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Res 504: 284–288
Lee CM, Tung WL and Young JD (1992) Tachykinin-stimulated inositol phospholipid hydrolysis and taurine release from human astrocytoma cells. J Neurochem 59: 406–414
Luo W, Sharif TR and Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56: 4983–4991
Maggi CA, Patacchini R, Rovero P and Giachetti A (1993) Tachykinin receptors and tachykinin receptor antagonists. J Autonom Pharmacol 13: 23–93
Mantyh PW, Johnson DJ, Boehmer CG, Catton MD, Vinters HV, Maggio JE, Too HP and Vigna SR (1989) Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci USA 86: 5193–5197
Masanao M (1998) Expression of multidrug resistance-associated protein (MRP) in human gliomas. Kanazawa Daigaku Juzen Igakkai Zasshi 107: 33–43
Michel JP, Sakamoto N, Bouvier R, Tommasi M and Pearson J (1986) Substance P-immunoreactive astrocytes related to deep white matter and striatal blood vessels in human brain. Brain Res 377: 383–387
Munoz-Fernandes MA and Fresno P (1993) Involvement of nitric oxide on the cytokine induced growth of glial cells . Biochem Biophys Res Commun 194: 319–325
Ogo H, Kuroyanagi N, Inoue A, Nishio H, Hirai Y, Akiyama M, DiMaggio DA, Krause JE and Nakata Y (1996) Human astrocytoma cells (U87 MG) exhibit a specific substance P binding site with the characteristics of an NK1 receptor. J Neurochem 67: 1813–1820
Otsuka M and Toshioka K (1993) Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73: 229–308
Palma C and Manzini S (1998) Substance P induces secretion of immunomodulatory cytokines by human astrocytoma cells. J Neuroimmunol 81: 127–137
Palma C, Urbani F and Manzini S (1995) Interleukin-6 production by U373 MG, a human astrocytoma cell line: different pathways involved in substance P and lipopolysaccharide activation. J Neuroimmunol 59: 155–163
Palma C, Minghetti L, Astolfi M, Ambrosini E, Ceccherini Silberstein F, Manzini S, Levi G and Aloisi F (1997) Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2production. Glia 21: 183–193
Palma C, Nardelli F, Manzini S and Maggi CA (1999 a) Substance P activates responses correlated with tumor growth in human glioma cell lines bearing tachykinin NK1receptors. Br J Cancer 79: 236–243
Palma C, Nardelli F and Manzini S (1999 b) Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1receptor antagonists. Eur J Pharmacol 374: 435–443
Quartara L and Maggi CA (1998) The tachykinin NK1receptor: Part II. Distribution and pathophysiological role. Neuropeptides 32: 1–49
Salcman M and Kaplan RS (1986) Intracranial tumors in adults. In: Comprehensive Textbook of Oncology, Moosa AR, Robson MC, Schimpff SC (eds), pp. 617–629. Williams and Wilkins: Baltimore
Shapiro WR, Shapiro JR and Walker RW (1995) Central nervous system. In: Clinical Oncology, Abeloff MD, Armitage JO, Licther AS, Niederhuber JE (eds), pp. 851–912. Churchill Livingstone: Edinburgh
Sharif M (1998) Mitogenic signaling by substance P and bombesine-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines. Int J Oncol 12: 273–286
Sharif TR, Luo W, Houghton PJ and Sharif M (1996) Substance K peptide induces mitogenesis by activating the mitogen-activated protein kinase signaling pathway through the substance P receptor (NK-1 subtype) in human astrocytoma. Cell Pharmacol 3: 441–449
Too HP, Marriott DR and Wilkin GP (1994) Preprotachykinin-A and substance P receptor (NK1) gene expression in rat astrocytes in vitro. Neurosci Lett 195: 57–60
Walther W, Stein U and Pfeil D (1995) Gene transfer of human TNF-alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity. Int J Cancer 61: 832–839
Yamazaki K, Moriya H, Ichihara N, Mitsushio H, Inagaki S and Kikuchi T (1993) Substance P-immunoreactive astrocytes in gracile sensory nervous tract of spinal cord in gracile axonal dystrophy mutant mouse. Mol Chem Neuropathol 20: 1–20
Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G and Maggi CA (1990) Substance P stimulates neovascularisation in vivo and proliferation of cultured endothelial cells. Microvasc Res 40: 264–278
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Palma, C., Bigioni, M., Irrissuto, C. et al. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82, 480–487 (2000). https://doi.org/10.1054/bjoc.1999.0946
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0946
Keywords
This article is cited by
-
Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists
Investigational New Drugs (2019)
-
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells
Journal of Neuro-Oncology (2016)
-
The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs
Journal of Biosciences (2015)
-
Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood–brain barrier during extravasation and brain invasion
Clinical & Experimental Metastasis (2013)
-
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines
Investigational New Drugs (2012)